Patient Services as an Evidence Engine: Rethinking how pharmaceutical and biotech companies capture and use patient support program data

Patient Services can help with the “messy middle”

Manufacturers already invest heavily in trials, registries, and post-market evidence. Patient services can add a different view providing insights into the messy middle of treatment.

Clinical trials are essential, but they do not fully capture routine care, where patients navigate insurance complexity, manage self-administration, fit treatment into daily life, and contend with uncertainty between appointments.

This is especially important for self-administered specialty products, infused therapies with complex logistics, rare disease treatments with high education needs, chronic therapies where persistence is a major challenge, and products with complicated onboarding or distribution pathways.

In these categories, patient services may be one of the organization’s closest views into the day-to-day experience of therapy.

It can reveal not only whether patients remained on treatment, but why they hesitated, which barriers mattered most, where the support model fell short, which interventions changed behavior, and what patients needed that brand teams may not have anticipated.

That makes patient services commercially relevant, medically relevant, and strategically valuable.

The important caveat: data is not the same as evidence

One thing has to be perfectly clear. A large support program does not automatically produce evidence simply because it produces data.

Many patient services datasets were built for operations rather than analytics. Common issues include inconsistent definitions across vendors or channels, unstructured notes, incomplete follow-up, selection bias, limited linkage to outcomes, and weak alignment among patient services, medical, and analytics teams. These limitations matter because pharma operates in a highly scrutinized environment.

If companies want to position patient services as an evidence engine, they need greater discipline in how data is captured, governed, analyzed, and interpreted.

A useful parallel is the evolution of electronic health record data into real-world data. Companies such as Flatiron Health demonstrated that the value was not in the existence of clinical records alone, but in the disciplined curation, standardization, and governance required to make those records analytically usable. Flatiron built its position around oncology-specific Electronic Health Records (EHR) software and the curation and development of real-world evidence for cancer research; Roche’s 2018 acquisition of Flatiron Health was one visible signal of how strategically important curated real-world data (RWD) had become to evidence generation.

Patient services data is different in source and purpose, but the lesson is highly relevant: value comes from converting fragmented, operationally generated information into a curated, fit-for-purpose evidence asset. The opportunity is not simply to collect more patient services data. It is to design patient services with the same seriousness that the RWD market applied to EHR data: clear use cases, consistent definitions, data quality controls, appropriate consent and governance, and the ability to link insights to decisions.

The next step for patient services is therefore to define a minimum viable evidence dataset. This does not need to be a universal standard applied identically across every therapy area, but it should establish a common baseline for the information that must be captured consistently if patient services data is to move beyond operational reporting. At minimum, this should include patient context, treatment journey milestones, access and affordability barriers, support interventions, patient-reported needs, persistence and discontinuation, relevant outcome or proxy outcome fields, and data quality and governance metadata (See Exhibit 1).

In short, patient services should not be treated as a shortcut to evidence. It should be designed as an evidence capability.

What a well-designed program needs to produce usable data

To make patient services data analytically useful, programs must be designed with evidence generation in mind from the outset. This does not mean turning every support program into a formal research study. It means building the operating model, data model, and governance framework so information captured through routine support can be interpreted consistently, responsibly, and with sufficient context.

A clear learning agenda should define the business, medical, access, or evidence questions the program is expected to inform before data collection begins. The program then needs a minimum structured dataset with consistent definitions for enrollment status, access barriers, benefit investigation outcomes, prior authorization steps, affordability support, treatment start, persistence, discontinuation, and patient-reported needs. It also needs standardized workflows across vendors, hubs, specialty pharmacies, nurse teams, digital tools, and field-facing channels so similar interactions are recorded consistently.

Patient-reported inputs should be captured deliberately and repeatably where appropriate, including barriers, confidence, burden, education needs, preferences, and reasons for non-initiation or discontinuation. Data quality controls are equally important, including completeness checks, validation rules, audit trails, source documentation, and routine monitoring for missingness, duplication, and inconsistent coding.

Usable data also depends on consent, privacy, and governance processes that define how data may be used, who can access it, how it may be linked, and which standards apply for de-identification, reuse, and reporting. Where permitted, linkage and interoperability plans should connect patient services data with other real-world sources such as claims, specialty pharmacy records, electronic health records, registries, or outcomes datasets. Cross-functional ownership is essential, as are pre-specified analytic approaches and feedback loops that translate insights into better support design, targeted interventions, field education, payer strategy, and future evidence planning.

These components separate programs that merely accumulate operational activity from those that generate usable insight. Without them, patient services data may be useful for running the program, but difficult to compare patients, vendors, regions, or time periods. With them, patient services become a more credible source of real-world learning because the data are more complete, traceable, interpretable, and fit for purpose.

The strategic opportunity for pharma

The strategic opportunity is to stop treating patient services as a downstream execution layer and start integrating it into brand, access, medical, and evidence strategy.

That shift has several implications.

• First, patient services should be involved earlier in launch planning, not added after access challenges emerge.
• Second, brand teams should look beyond enrollment and persistence metrics to understand what patient services can reveal about treatment experience and unmet needs.
• Third, medical, HEOR, market access, and commercial teams should align around a shared learning agenda rather than use patient services data in silos.

Finally, leaders should ask a more ambitious question:

Are our patient services programs only helping patients start therapy, or are they also helping us improve the treatment journey itself?

The next generation of patient services will be judged not only by how efficiently it processes cases or how quickly it helps patients start therapy, but by whether it creates a better understanding of the real-world treatment journey and translates that understanding into better support, stronger evidence, and a more credible value story.

Biopharma leaders should assess their patient services programs now against a higher standard that goes beyond whether they support access and asks whether they generate reliable, governed, and actionable insight. The organizations that design patient services with this discipline will be better positioned to improve the patient journey, strengthen evidence planning, and make the product value story more credible in the real world.